Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
At StockStory, we dig beneath the surface of price movements to uncover whether a company's fundamentals justify its current valuation or suggest hidden potential. That said, here is one stock poised to prove the bears wrong and two where the outlook is warranted.
Two Stocks to Sell:
PlayStudios (MYPS)
One-Month Return: -13.6%
Founded by a team of former gaming industry executives, PlayStudios (NASDAQ: MYPS) offers free-to-play digital casino games.
Why Do We Steer Clear of MYPS?
- Annual sales declines of 2.7% for the past five years show its products and services struggled to connect with the market
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Returns on capital are increasing as management makes relatively better investment decisions
PlayStudios’s stock price of $0.43 implies a valuation ratio of 0.3x forward price-to-sales. Check out our free in-depth research report to learn more about why MYPS doesn’t pass our bar.
Insteel (IIIN)
One-Month Return: -20.9%
Growing from a small wire manufacturer to one of the largest in the U.S., Insteel (NYSE: IIIN) provides steel wire reinforcing products for concrete.
Why Does IIIN Worry Us?
- Annual revenue growth of 5.9% over the last five years was below our standards for the industrials sector
- Free cash flow margin shrank by 5 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability
At $25.93 per share, Insteel trades at 14.5x forward P/E. To fully understand why you should be careful with IIIN, check out our full research report (it’s free).
One Stock to Buy:
Insulet (PODD)
One-Month Return: -9.8%
Revolutionizing diabetes care with its tubeless "Pod" technology, Insulet (NASDAQ: PODD) develops and manufactures innovative insulin delivery systems for people with diabetes, primarily through its Omnipod product line.
Why Do We Love PODD?
- Average constant currency growth of 25.9% over the past two years demonstrates its ability to grow internationally despite currency fluctuations
- Free cash flow margin expanded by 30.1 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
- Improving returns on capital reflect management’s ability to monetize investments
Insulet is trading at $187.63 per share, or 29.9x forward P/E. Is now a good time to buy? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
